Here is what the cited sources show: - LL-37 is the only human cathelicidin-derived antimicrobial peptide and a central effector of innate immunity. It is generated by proteolytic cleavage of the hCAP18 precursor and is expressed by neutrophils, epithelial… [1] - AOD-9604 is a modified fragment of growth hormone (hGH 176-191) studied for lipolytic effects. Mechanism: proposed stimulation of lipolysis and inhibition of lipogenesis without significant effect on IGF-1; metabolic/… [2] - Lyme disease (Borrelia) and tick-borne co-infections (Bartonella, Babesia) can produce overlapping multisystem, relapsing-remitting presentations. Persistent symptoms after treatment ("PTLDS") remain debated. Co-infec… [3] - Mechanism: proposed stimulation of lipolysis and inhibition of lipogenesis without significant effect on IGF-1; metabolic/cartilage effects explored in models. [4] - 200-600 mg per injection (IM/SC); 600-1400 mg per session (IV push); 500-1000 mg daily (oral) · subcutaneous or intranasal or oral or topical or intramuscular [5] - Standard: 5 mg once weekly · Low: 2.5 mg once weekly · High: 15 mg once weekly · Subcutaneous injection [6] - 2.5 mg starting dose, escalating to 5-15 mg maintenance · subcutaneous or oral [7] - 250-750 mg per IV session; 300-1000 mg daily for oral precursors (NR/NMN) · oral [8] This is decision support — a navigation of the cited sources, not a diagnosis, recommendation, or directive. Open the cited sources to verify.